Disease · MONDO_0005034

thyroid gland follicular carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. thyroid gland follicular carcinoma. Diseases, record MONDO_0005034. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005034

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: thyroid gland follicular carcinoma; Open Targets
Open Targets ID: MONDO_0005034; Open Targets
Other names: carcinoma of thyroid follicle, carcinoma, follicular cell, malignant, follicular adenocarcinoma, follicular adenocarcinoma (morphologic abnormality), follicular adenocarcinoma, well differentiated, follicular adenocarcinoma, well differentiated (morphologic abnormality), follicular cancer of the thyroid, follicular cancer of the thyroid gland, follicular cancer of thyroid, follicular cancer of thyroid gland, follicular carcinoma, follicular carcinoma of the thyroid, follicular carcinoma of the thyroid gland, follicular carcinoma of thyroid, follicular carcinoma of thyroid gland, follicular thyroid cancer, follicular thyroid carcinoma, follicular thyroid gland carcinoma, thyroid follicle carcinoma, thyroid follicular carcinoma, thyroid gland adenocarcinoma, thyroid gland follicular cancer, well-differentiated follicular adenocarcinoma, well-differentiated follicular carcinoma; Open Targets
Disease Ontology: DOID:3962; Disease Ontology
MeSH: D018263; MeSH
NCI Thesaurus: C8054; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 27 drugs, from ClinicalTrials.gov; Open Targets

Drugs27

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IODINE	CHEMBL1201225	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RIVOCERANIB	CHEMBL3186534	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VANDETANIB	CHEMBL24828	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BUPARLISIB	CHEMBL2017974	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CM-4307	CHEMBL4297490	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CRIZOTINIB	CHEMBL601719	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 27

See all 27 drugs

Targets125

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
RET	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET	3	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
ALK	ALK tyrosine kinase receptor	2	ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor	Phase 2	https://conductscience.org/library/genes/238	Drugs and targets
BRAF	Serine/threonine-protein kinase B-raf	2	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	2	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets

1 to 10 of 125

See all 125 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00537095	Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer	Phase 2	164	2011-07-08	Thyroid Neoplasms	VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT00923481	A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	Phase 2	37	2012-08-29	Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell	FOSTAMATINIB DISODIUM	Its record names the disease	ClinicalTrials.gov
NCT00251316	Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer	Phase 2	34	2012-12-27	Thyroid Cancer, Differentiated Thyroid Carcinoma	LITHIUM CARBONATE	Its record names the disease	ClinicalTrials.gov
NCT00287287	REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas	Phase 2	25	2020-06-12	Thyroid Neoplasms	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00104871	Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy	Phase 2	24	2014-06-25	Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer	BORTEZOMIB	Its record names the disease	ClinicalTrials.gov
NCT00085293	Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131	Phase 2	12	2014-09-01	Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer	DECITABINE	Its record names the disease	ClinicalTrials.gov
NCT02034981	Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1	Phase 2	246		Hematologic Cancers, Solid Tumors, Metastatic Cancer	CRIZOTINIB	Its record names the disease	ClinicalTrials.gov
NCT01813136	Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma	Phase 2	168		Thyroid Carcinoma	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT06482086	Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer	Phase 2	75		Locally Advanced Thyroid Gland Carcinoma	CABOZANTINIB, CATEQUENTINIB, CM-4307, DABRAFENIB, ENTRECTINIB, EVEROLIMUS, LAROTRECTINIB, LENVATINIB, PRALSETINIB, RIVOCERANIB, SORAFENIB, TRAMETINIB, VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT00786552	Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer	Phase 2	47		Thyroid Cancer	PACLITAXEL, PEMETREXED	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ZD6474 vs PLACEBO: Objective Response Rate	6 of 72	4 of 73	145	NCT00537095	Trial comparisons
ZD6474 vs PLACEBO: Time to Death	19 of 72	21 of 73	145	NCT00537095	Trial comparisons
ZD6474 vs PLACEBO: Disease Control Rate at 6 Months	41 of 72	31 of 73	145	NCT00537095	Trial comparisons
Lithium Carbonate vs Placebo: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year.	10 of 15	10 of 14	29	NCT00251316	Trial comparisons
Lithium Carbonate vs Placebo: serious adverse events	0 of 15	1 of 14	29	NCT00251316	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40304938	DERIVED	1	PubMed
37549532	DERIVED	1	PubMed
35767182	DERIVED	1	PubMed
34509954	DERIVED	1	PubMed
33847874	DERIVED	1	PubMed
31584608	DERIVED	1	PubMed
30105951	DERIVED	1	PubMed
22898678	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005034

GET https://conductscience.org/api/diseases/v1/MONDO_0005034/drugs?page=2

API reference For AI assistants